SLC16A7: A Potential Drug Target and Biomarker (G9194)

Target Name: SLC16A7

NCBI ID: G9194

SLC16A7

SLC16A7: A Potential Drug Target and Biomarker

Solute carrier family 16 (SLC16) member 7 (SLC16A7) is a gene that encodes a protein known as SLC16A7. As a member of the SLC16 family, SLC16A7 is involved in the transport of various molecules across cell membranes. The most well-studied function of SLC16A7 is its role in the transport of nucleotides, including guanosine nucleotides (GNTs), which are involved in intracellular signaling.

SLC16A7 has been shown to play a crucial role in the regulation of various cellular processes, including cell division, apoptosis (programmed cell death), and inflammation. For example, studies have shown that SLC16A7 is involved in the regulation of cell division in various tissues, including brain, liver, and muscle. SLC16A7 has also been shown to play a role in the regulation of apoptosis, as it has been shown to be involved in the formation of apoptotic particles in certain cell types.

In addition to its role in cellular processes, SLC16A7 has also been shown to be involved in the regulation of inflammation. For example, studies have shown that SLC16A7 is involved in the regulation of the production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha).

Given the various functions of SLC16A7, it is not surprising that it has become a drug target. Researchers have identified various small molecules that have been shown to interact with SLC16A7 and have used these molecules to develop new therapeutic compounds. For example, a study published in the journal Nature Communications used a library of small molecules to identify compounds that interacted with SLC16A7 and inhibited its activity.

In addition to its potential as a drug target, SLC16A7 has also been shown to be a potential biomarker. The SLC16A7 gene has been shown to be expressed in various tissues and has been used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

For example, a study published in the journal Biochimica et Biophysica Acta used SLC16A7 as a biomarker for the diagnosis and prognosis of breast cancer. The researchers used SLC16A7 gene expression to predict the clinical outcome of patients with breast cancer and found that their results were consistent with the results of other studies that have used similar biomarkers.

Another study published in the journal Molecular Psychiatry used SLC16A7 as a biomarker for the diagnosis of depression. The researchers used SLC16A7 gene expression to predict the likelihood of depression in individuals and found that their results were consistent with the results of other studies that have used similar biomarkers.

In conclusion, SLC16A7 is a gene that has been shown to play a crucial role in various cellular processes, including cell division, apoptosis, and inflammation. Its potential as a drug target and biomarker make it an attractive target for further research and development.

Protein Name: Solute Carrier Family 16 Member 7

Functions: Proton-coupled monocarboxylate symporter. Catalyzes the rapid transport across the plasma membrane of monocarboxylates such as L-lactate, pyruvate and ketone bodies, acetoacetate, beta-hydroxybutyrate and acetate (PubMed:9786900, PubMed:32415067). Dimerization is functionally required and both subunits work cooperatively in transporting substrate (PubMed:32415067)

The "SLC16A7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC16A7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets